Of the 25 isolates with caspofungin MICs of >1 g/ml, 12 isolates were C. parapsilosis, 6 isolates were C. guilliermondii, 2 isolates were C. rugosa, and 1 isolate each was C. albicans, C. glabrata, C. krusei, C. lusitaniae, and C. tropicalis. There was no significant change in caspofungin activity over the 4-year study period. Likewise, there was no difference in activity by geographic region. Caspofungin has excellent in vitro activity against invasive clinical isolates of Candida from centers worldwide. Our prospective sentinel surveillance reveals no evidence of emerging caspofungin resistance among invasive clinical isolates of Candida.
Caspofungin is the first of three new echinocandin antifungal agents to become available for the treatment of invasive mycoses (3, 7, 11, 17, 19, 21, 22, 26, 28) . Like other echinocandins, caspofungin acts via inhibition of 1,3-␤-D-glucan synthase, an enzyme necessary for the formation of the essential cell wall component of Candida and other important fungal pathogens (3) . First introduced in 2001, caspofungin is now approved for the treatment of candidemia and other forms of invasive candidiasis, treatment of invasive aspergillosis in patients refractory to or intolerant of other licensed antifungal agents, and empirical antifungal therapy of febrile neutropenia (1, 13, 14, 27) . The potent, broad-spectrum fungicidal activity of caspofungin against Candida spp. has led to extensive use of this agent for the treatment of all forms of serious candidal infections over the past 4 years (9, 12, 17, 25) . Thus far, clinical experience with caspofungin and invasive candidiasis has been good (9, 14, 17) . However, recent reports describing the emergence of caspofungin resistance during treatment of esophagitis (6) and endocarditis (15) raise concerns about the potential emergence of caspofungin-resistant Candida species. Specific mutations in the FKS1 genes (which encode essential components of the glucan synthase complex) have been found to confer resistance to echinocandins among Candida spp. (10, 20) . Ongoing surveillance of the activity of caspofungin and other echinocandins will be important as these agents are used more broadly worldwide.
The optimization of in vitro susceptibility testing of caspofungin against Candida spp. has been a difficult process (2) . A recent multicenter (17-laboratory) study by Odds and colleagues (18) indicated that the optimal method for testing caspofungin against Candida spp. included the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) broth microdilution method with RPMI 1640 broth, incubation for no longer than 24 h, and an MIC endpoint criterion of prominent reduction in growth (MIC-2, defined as Ն50% inhibition relative to control growth) (16, 18) . These testing conditions not only provided excellent reproducibility of results within and between laboratories but were also sufficient to differentiate isolates with "normal" or "wild-type" susceptibilities from glucan synthesis mutant strains with decreased susceptibilities to caspofungin. These results were further validated by a subsequent study using a large (3,322-isolate) international collection of Candida spp. (23) . The latter isolate collection represented bloodstream infection isolates of Candida spp. collected from Ͼ100 medical centers prior to the introduction of caspofungin (1992 to 2000); thus, the MIC distribution profile may be considered to represent the "wild-type" distribution for caspofungin and Candida (8) .
In the present study, we have employed the optimal testing conditions, as described by Odds et al. (18) zeylanoides. All isolates were obtained from blood or other normally sterile sites, and each represented an individual infectious episode. The isolates were collected at the individual study sites and were sent to the University of Iowa (Iowa City) for identification and susceptibility testing as described previously (24) . The isolates were identified by standard methods (5) and stored as water suspensions until used in the study. Prior to testing, each isolate was passaged at least twice onto potato dextrose agar (Remel) and CHROMagar Candida (Hardy Diagnostics, Santa Maria, Calif.) to ensure purity and viability.
Antifungal agents. Reference powder of caspofungin was obtained from Merck. Stock solutions were prepared in water, and serial twofold dilutions were prepared exactly as outlined in CLSI document M27-A2 (16) . Final dilutions were made in RPMI 1640 medium (Sigma, St. Louis, Mo.) buffered to pH 7.0 with 0.165 M morpholenepropanesulfonic acid (MOPS) buffer (Sigma).
Antifungal susceptibility testing. Broth microdilution testing was performed in accordance with the guidelines in CLSI document M27-A2 (16) using RPMI 1640 medium, an inoculum of 0.5 ϫ 10 3 to 2.5 ϫ 10 3 cells per ml, and incubation at 35°C. MICs were determined visually after 24-h incubation as the lowest concentration of drug that caused a significant diminution (MIC-2 or Ն50%) of growth below growth control levels (18, 23) .
Quality control. Quality control was performed by testing the CLSI-recommended strains C. krusei ATCC 6258 and C. parapsilosis ATCC 22019 (16) . Second, as was seen previously (23), the MIC distributions identified two broad groups among the nine different species tested. The most susceptible species (MIC 90 , 0.03 to 0.06 g/ml) were C. albicans, C. glabrata, C. tropicalis, C. kefyr, and C. pelliculosa, whereas C. parapsilosis (MIC 90 , 0.5 g/ml), C. guilliermondii (MIC 90 , 1 g/ml), C. krusei (MIC 90 , 0.5 g/ml), and C. lusitaniae (MIC 90 , 0.5 g/ml) were all significantly less susceptible to caspofungin. These data are essentially identical to those reported previously for a smaller collection of isolates (23) and suggest that there may be a biological difference in the susceptibility of these two groups of Candida to caspofungin. This difference is likely due to differences in the sensitivity of the glucan synthesis enzyme complex of each species to inhibition by caspofungin (4, 10) . Limited data suggest that the species within these two groups both respond to caspofungin treatment (9, 14) , and MICs for Ͼ99% of isolates in both groups were Յ1 g/ml. In contrast, MICs for strains of Candida with documented FKS1 gene mutations (18, 23) and for those published resistant strains (6, 15) were all Ͼ2 g/ml and were usually Ͼ8 g/ml.
RESULTS AND DISCUSSION
The caspofungin susceptibility of isolates stratified by geographic region and by species is shown in Table 2 . Among the 91 medical centers contributing isolates, 16 were located in the Asia-Pacific region, 32 were in Europe, 15 were in Latin America, and 28 were in North America. In each of the geographic regions, C. albicans accounted for approximately 50% of the isolates submitted for testing; however, the percentage of isolates of non-C. albicans species varied considerably from region to region. Whereas C. glabrata was the most common non-C. albicans species in North America, it was surpassed by C. parapsilosis and/or C. tropicalis in the other three regions. Interestingly, C. guilliermondii, a distinctly uncommon species of Candida throughout most of the world (0.4 to 1.5% of Candida isolates), was almost as common as C. glabrata (4.0% versus 6.5%, respectively) in Latin America. Despite these differences in species distribution, isolates of Candida from throughout the world were all comparably susceptible to caspofungin. The caspofungin susceptibility profile of all 8,197 isolates of Candida spp. submitted for testing between 2001 and 2004 was unchanged over the 4-year study period, with Ͼ99% of isolates tested in each year inhibited by Յ1 g/ml (Table 3 ). This MIC distribution was virtually identical to the "wild-type" MIC distribution reported previously (23) for isolates collected in years prior to the introduction of caspofungin (1992 to 2000) (Table  3) . Thus, despite the recent case reports of caspofungin resistance developing during treatment of complicated candidal infections (6, 15) , there was no evidence for a shift in the caspofungin MIC distribution profile towards higher MICs over the most recent 4-year period.
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